Aldeyra Therapeutics Inc. (ALDX)
2.24
0.05 (2.28%)
At close: Apr 21, 2025, 3:59 PM
2.29
2.23%
Pre-market: Apr 22, 2025, 04:10 AM EDT
2.28% (1D)
| Bid | 2.18 |
| Market Cap | 133.75M |
| Revenue (ttm) | 244.53K |
| Net Income (ttm) | -55.85M |
| EPS (ttm) | -0.94 |
| PE Ratio (ttm) | -2.38 |
| Forward PE | -3.84 |
| Analyst | Buy |
| Ask | 2.33 |
| Volume | 999,500 |
| Avg. Volume (20D) | 1,497,919 |
| Open | 1.90 |
| Previous Close | 2.19 |
| Day's Range | 2.13 - 2.35 |
| 52-Week Range | 1.14 - 7.20 |
| Beta | 0.93 |
About ALDX
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical tria...
Industry Biotechnology
Sector Healthcare
IPO Date May 2, 2014
Employees 9
Stock Exchange NASDAQ
Ticker Symbol ALDX
Website https://www.aldeyra.com
Analyst Forecast
According to 3 analyst ratings, the average rating for ALDX stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 346.43% from the latest price.
Stock Forecasts2 weeks ago
-73.36%
Aldeyra Therapeutics shares are trading lower afte...
Unlock content with
Pro Subscription
5 months ago
+11.64%
Aldeyra Therapeutics shares are trading higher after the FDA accepted its resubmitted new drug application for Reproxalap for the treatment of dry eye disease, prompting the company to announce an expansion of its option agreement with AbbVie.
